echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Researchers develop intravenous therapy for sepsis

    Researchers develop intravenous therapy for sepsis

    • Last Update: 2022-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Researchers at Purdue's School of Pharmacy and Engineering are developing a patent-pending treatment that could impact the lives of millions of Americans each year


    The Centers for Disease Control and Prevention reports that at least 1.


    A Purdue University team led by Yoon Yeo has developed biocompatible nanoparticles to treat sepsis through an intravenous system


    Polymyxin B, a traditional antibiotic that inactivates endotoxins that cause certain types of sepsis, may be too toxic for systemic application, Yeo said


    "Our nanoparticle formulation reduced the dose-limiting toxicity of polymyxin B without losing its ability to inactivate endotoxin," Yeo said


    In a mouse model of sepsis, 100 percent of mice treated with Purdue nanoparticles were spared from excessive inflammation and survived


    "This technology promises to be a safe, convenient option for patients and physicians



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.